Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> Rearrangement
Srđan Verstovšek(The University of Texas MD Anderson Cancer Center), Jason Gotlib(Stanford University), Jean‐Jacques Kiladjian(Assistance Publique – Hôpitaux de Paris), Tracy I. George(University of Utah), Aidan G. Gilmartin(GlaxoSmithKline (United States)), Kensuke Usuki(Teikyo University Hospital), Andreas Reiter(Heidelberg University), Hui‐Ling Zhen(Incyte (United States)), Jay Patel(Memorial Sloan Kettering Cancer Center), Alessandro M. Vannucchi(University of Florence), Claire Harrison(University of Namur), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Juan Carlos Hernández‐Boluda(Hospital Clínico Universitario de Valencia), Philomena Colucci(Incyte (United States)), Ellen K. Ritchie(Cornell University), William Shomali(Stanford Medicine), Luke P. Akard(Franciscan Health Indianapolis), Cheryl Langford(Stanford University), Stephen T. Oh(Washington University in St. Louis), Natália Oliveira(Incyte (United States)), Françoise Huguet(European Union)
Cited by 7
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k